Objective: Caudate atrophy rate measured from serial MRI is proposed as a biomarker of HD progression that may be of use in assessing putative disease-modifying agents. Manual measurement techniques ...are the most widely applied but are time-consuming. We describe and evaluate an automated technique based on a local registration and boundary shift integral (BSI) approach at the caudate–CSF and caudate–white matter boundaries; caudate boundary shift integral (CBSI). Methods: Two-year caudate volume change was measured in controls, premanifest HD and early HD using the CBSI and compared with a detailed manual measure in terms of 1) raw caudate volume change, 2) group differentiation, 3) associations with clinical variables and 4) rater requirements. CBSI additivity was assessed by comparing measurements over a single scan pair (baseline→2 years), with the sum of measurements from two scan pairs (baseline→1 year→2 years). Results: Techniques produced comparable caudate volume change measurements, although CBSI under-reported by 0.04 ml relative to manual. Both techniques distinguished controls, premanifest and early HD with a stepwise increase in rates across groups. Higher rates (CBSI and manual) were associated with increased proximity to estimated disease onset but not clinical change scores. CBSI reduced rater requirements by 2/3 (2 h per subject) relative to manual for this three time-point investigation. CBSI measurements over one scan pair showed good agreement with the sum of measurements from two scan pairs. Conclusions: CBSI results were comparable to a manual measure but with reduced rater requirements. CBSI may be of use in large-scale studies of HD.
Abstract
We investigated whether subtle visuomotor deficits were detectable in familial and sporadic preclinical Alzheimer’s disease. A circle-tracing task—with direct and indirect visual feedback, ...and dual-task subtraction—was completed by 31 individuals at 50% risk of familial Alzheimer’s disease (19 presymptomatic mutation carriers; 12 non-carriers) and 390 cognitively normal older adults (members of the British 1946 Birth Cohort, all born during the same week; age range at assessment = 69–71 years), who also underwent β-amyloid-PET/MRI to derive amyloid status (positive/negative), whole-brain volume and white matter hyperintensity volume. We compared preclinical Alzheimer’s groups against controls cross-sectionally (mutation carriers versus non-carriers; amyloid-positive versus amyloid-negative) on speed and accuracy of circle-tracing and subtraction. Mutation carriers (mean 7 years before expected onset) and amyloid-positive older adults traced disproportionately less accurately than controls when visual feedback was indirect, and were slower at dual-task subtraction. In the older adults, the same pattern of associations was found when considering amyloid burden as a continuous variable (Standardized Uptake Value Ratio). The effect of amyloid was independent of white matter hyperintensity and brain volumes, which themselves were associated with different aspects of performance: greater white matter hyperintensity volume was also associated with disproportionately poorer tracing accuracy when visual feedback was indirect, whereas larger brain volume was associated with faster tracing and faster subtraction. Mutation carriers also showed evidence of poorer tracing accuracy when visual feedback was direct. This study provides the first evidence of visuomotor integration deficits common to familial and sporadic preclinical Alzheimer’s disease, which may precede the onset of clinical symptoms by several years.
Using a computerized circle-tracing task with direct and indirect visual feedback, Lu et al. report the first evidence of visuomotor integration deficits in both familial and sporadic preclinical Alzheimer’s disease groups, suggesting that these deficits might precede the onset of clinical symptoms by several years.
Graphical Abstract
Graphical Abstract
Biomarkers for neurodegenerative diseases Henley, Susie M D; Bates, Gillian P; Tabrizi, Sarah J
Current opinion in neurology,
12/2005, Letnik:
18, Številka:
6
Journal Article
Recenzirano
Odprti dostop
A major goal of current clinical research in neurodegenerative diseases is to improve early detection of disease and presymptomatic detection of neuronal dysfunction. We also need better tools to ...assess disease progression in this group of disorders. Currently, many potential disease-modifying therapies are being developed and evaluated at the preclinical stage, and will lead to clinical trials in the near future for which biomarkers are urgently needed. This review summarizes the field of biomarker research in the major neurodegenerative diseases.
Many different approaches are being undertaken to identify biomarkers and include imaging, neurophysiological and cognitive testing in addition to newer technologies such as biochemical, proteomic, metabanomic and gene array profiling of tissue and biofluids from patients. Key recent findings in each of these areas are discussed.
The ideal biomarker needs to be easy to quantify and measure, reproducible, not subject to wide variation in the general population and unaffected by co-morbid factors. For evaluation of therapies the biomarker needs to change linearly with disease progression and closely correlate with established clinico-pathological parameters of the disease. It is unlikely that any one biomarker will fulfil all these characteristics, and it is likely that more than one biomarker will be needed for early diagnosis and similarly for evaluation of disease progression for therapeutic trials. For example, the combination of more detailed clinical assessments encompassing specific cognitive and neurophysiological testing, in addition to imaging, biochemical and genomic profiling, is likely to be needed.
Recognition of negative emotions is impaired in Huntington׳s Disease (HD). It is unclear whether these emotion-specific problems are driven by dissociable cognitive deficits, emotion complexity, test ...cue difficulty, or visuoperceptual impairments. This study set out to further characterise emotion recognition in HD by comparing patterns of deficits across stimulus modalities; notably including for the first time in HD, the more ecologically and clinically relevant modality of film clips portraying dynamic facial expressions.
Fifteen early HD and 17 control participants were tested on emotion recognition from static facial photographs, non-verbal vocal expressions and one second dynamic film clips, all depicting different emotions.
Statistically significant evidence of impairment of anger, disgust and fear recognition was seen in HD participants compared with healthy controls across multiple stimulus modalities. The extent of the impairment, as measured by the difference in the number of errors made between HD participants and controls, differed according to the combination of emotion and modality (p=0.013, interaction test). The largest between-group difference was seen in the recognition of anger from film clips.
Consistent with previous reports, anger, disgust and fear were the most poorly recognised emotions by the HD group. This impairment did not appear to be due to task demands or expression complexity as the pattern of between-group differences did not correspond to the pattern of errors made by either group; implicating emotion-specific cognitive processing pathology. There was however evidence that the extent of emotion recognition deficits significantly differed between stimulus modalities. The implications in terms of designing future tests of emotion recognition and care giving are discussed.
•Recognition of negative emotions is impaired in Huntington׳s Disease.•It is unclear whether this deficit is consistent across stimulus modalities.•Emotion recognition from photo, vocal and film cues was tested in HD and controls.•Varying patterns of impairment were found across modalities.•Emotion recognition deficits are valence and modality specific in HD.
Impairments of social cognition are often leading features in frontotemporal lobar degeneration (FTLD) and likely to reflect large-scale brain network disintegration. However, the neuroanatomical ...basis of impaired social cognition in FTLD and the role of white matter connections have not been defined. Here we assessed social cognition in a cohort of patients representing two core syndromes of FTLD, behavioural variant frontotemporal dementia (bvFTD; n = 29) and semantic variant primary progressive aphasia (svPPA; n = 15), relative to healthy older individuals (n = 37) using two components of the Awareness of Social Inference Test, canonical emotion identification and sarcasm identification. Diffusion tensor imaging (DTI) was used to derive white matter tract correlates of social cognition performance and compared with the distribution of grey matter atrophy on voxel-based morphometry. The bvFTD and svPPA groups showed comparably severe deficits for identification of canonical emotions and sarcasm, and these deficits were correlated with distributed and overlapping white matter tract alterations particularly affecting frontotemporal connections in the right cerebral hemisphere. The most robust DTI associations were identified in white matter tracts linking cognitive and evaluative processing with emotional responses: anterior thalamic radiation, fornix (emotion identification) and uncinate fasciculus (sarcasm identification). DTI associations of impaired social cognition were more consistent than corresponding grey matter associations. These findings delineate a brain network substrate for the social impairment that characterises FTLD syndromes. The findings further suggest that DTI can generate sensitive and functionally relevant indexes of white matter damage in FTLD, with potential to transcend conventional syndrome boundaries.
To evaluate the incidence of mosaicism in de novo neurofibromatosis 2 (NF2).
Patients fulfilling NF2 criteria, but with no known affected family member from a previous generation (n = 1055), were ...tested for NF2 variants in lymphocyte DNA and where available tumor DNA. The proportion of individuals with a proven or presumed mosaic NF2 variant was assessed and allele frequencies of identified variants evaluated using next-generation sequencing.
The rate of proven/presumed mosaicism was 232/1055 (22.0%). However, nonmosaic heterozygous pathogenic variants were only identified in 387/1055 (36.7%). When variant detection rates in second generation nonmosaics were applied to de novo cases, we assessed the overall probable mosaicism rate to be 59.7%. This rate differed by age from 21.7% in those presenting with bilateral vestibular schwannoma <20 years to 80.7% in those aged ≥60 years. A mosaic variant was detected in all parents of affected children with a single-nucleotide pathogenic NF2 variant.
This study has identified a very high probable mosaicism rate in de novo NF2, probably making NF2 the condition with the highest expressed rate of mosaicism in de novo dominant disease that is nonlethal in heterozygote form. Risks to offspring are small and probably correlate with variant allele frequency detected in blood.
Aims There is increasing interest in the nature of the emotion recognition deficit in Huntington’s disease (HD) with conflicting reports of disproportionate impairments for some emotions in some ...modalities. This review aimed to clarify the pattern of emotion recognition deficits in HD. Methods A systematic review and narrative synthesis was conducted for studies investigating emotion recognition in Huntington’s disease. Embase, MEDLINE, PsychINFO and PubMed were searched from 1993 to 2010, and citation and reference list searches were also conducted. 1724 citations were identified. Results Sixteen studies met inclusion criteria. In manifest HD recognition of facial anger was found most consistently, although recognition of all negative emotions (facial and vocal) tended to be impaired. In premanifest HD impairments were inconsistent, but are seen in all facial expressions of negative emotion. Inconsistency may represent the variability inherent in HD although may also be due to between-study differences in methodology. Conclusions Current evidence supports the conclusion that recognition of all negative emotions tends to be impaired in HD, particularly in the facial domain. Future work should focus on using more ecologically-valid tests, and testing inter-modality differences.
Background
While APOE‐ε4 carriers are at higher risk of Alzheimer’s disease (AD), there is evidence that APOE‐ε4 may have some beneficial effects across the life‐span, including on cognition. It is ...unclear how such effects may relate to subtle memory decline during the preclinical phase of AD. Two previous studies reported that APOE‐ε4 carriers recalled object locations more accurately than non‐carriers on the “What was where?” visual short‐term memory binding test (10.1016/j.cortex.2016.12.016; 10.1016/j.neurobiolaging.2018.09.017), but these studies did not account for preclinical AD pathology.
Method
The “What was where?” task (Figure 1) was administered to participants in Insight 46 – a sub‐study of the British 1946 birth cohort – who were all born during the same week (aged 69‐71 at assessment (Table 1)). Outcomes included object identification and a sensitive analogue measure of localisation error (the distance between the location reported by the participant and the true location). Two‐dimensional mixture models (10.31234/osf.io/q57fm) were used to isolate three sources of localisation error: imprecision, guessing, and misbinding (swapping an object’s location with that of a different object). β‐Amyloid status (positive / negative) was determined from 18F‐Florbetapir‐PET. Multivariable regression models were used to investigate differential effects of APOE genotype (ε4‐carrier / non‐carrier) and β‐amyloid status on performance in 398 cognitively‐normal participants, adjusting for confounders including a prospectively‐collected measure of childhood cognitive ability.
Result
APOE‐ε4 and β‐amyloid had opposing effects on object identification, with APOE‐ε4 predicting better recall and β‐amyloid‐positivity predicting poorer recall. APOE‐ε4 carriers also recalled object locations more precisely, but a subtle detrimental effect of β‐amyloid on localisation was seen only among non‐carriers (Table 2, Figure 2). Childhood cognitive ability also predicted performance over 60 years later (Table 2).
Conclusion
In this large population‐based sample of cognitively‐normal ∼70‐year‐olds, a positive association between APOE‐ε4 and short‐term visual memory was observed. For the localization measure, this appeared to be protective against a subtle deficit associated with β‐amyloid pathology. This is consistent with the antagonistic pleiotropy hypothesis – whereby a gene controls both beneficial and detrimental traits – and provides novel evidence that these effects persist into older age, even among individuals who may be in the preclinical stages of AD.